Cargando…
TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD
BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked inherited disease caused by mutations in the gene encoding dystrophin that leads to a severe and ultimately life limiting muscle-wasting condition. Recombinant adeno-associated vector (rAAV)-based gene therapy is promising, but the size of...
Autores principales: | Creisméas, Anna, Gazaille, Claire, Bourdon, Audrey, Lallemand, Marc-Antoine, François, Virginie, Allais, Marine, Ledevin, Mireille, Larcher, Thibaut, Toumaniantz, Gilles, Lafoux, Aude, Huchet, Corinne, Anegon, Ignacio, Adjali, Oumeya, Le Guiner, Caroline, Fraysse, Bodvaël |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686557/ https://www.ncbi.nlm.nih.gov/pubmed/34930315 http://dx.doi.org/10.1186/s12967-021-03191-9 |
Ejemplares similares
-
Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmd(mdx) rat model
por: Caudal, Dorian, et al.
Publicado: (2020) -
Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy
por: Le Guiner, Caroline, et al.
Publicado: (2023) -
The contribution of TRPC1, TRPC3, TRPC5 and TRPC6 to touch and hearing
por: Sexton, Jane E., et al.
Publicado: (2016) -
Corticolimbic Expression of TRPC4 and TRPC5 Channels in the Rodent Brain
por: Fowler, Melissa A., et al.
Publicado: (2007) -
Novel Targets for Stroke Therapy: Special Focus on TRPC Channels and TRPC6
por: Liu, Lu, et al.
Publicado: (2020)